Compare AMTD & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMTD | TIL |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.6M | 74.7M |
| IPO Year | 2019 | 2021 |
| Metric | AMTD | TIL |
|---|---|---|
| Price | $1.02 | $7.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | 44.2K | ★ 261.9K |
| Earning Date | 12-30-2025 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $119,304,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.28 | ★ N/A |
| Revenue Growth | ★ 154.24 | N/A |
| 52 Week Low | $0.87 | $5.67 |
| 52 Week High | $1.65 | $42.79 |
| Indicator | AMTD | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 49.26 | 31.91 |
| Support Level | $0.98 | $6.96 |
| Resistance Level | $1.05 | $7.36 |
| Average True Range (ATR) | 0.03 | 0.54 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 64.38 | 20.24 |
AMTD IDEA Group is a financial institution operating in five business segments: The capital market solutions segment assists customers in raising funds through equity and debt financing, private placements, and debt issuances. The digital solutions and other services segment provides institutional and corporate clients with paid access to enhance investor communication and relations, corporate communication also provides digital financial solution services. The Media and entertainment segment offers print and digital advertising campaigns, licensing, and marketing services including branded content, video production. The hotel operations, hospitality, and VIP services segment engages in hotel investments, hotel operations, hospitality, and VIP services; and Strategic investment segment.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.